DK3059314T3 - Antistofmolekyler, der har specificitet for human tumornekrosefaktor alpha, og anvendelse deraf - Google Patents

Antistofmolekyler, der har specificitet for human tumornekrosefaktor alpha, og anvendelse deraf Download PDF

Info

Publication number
DK3059314T3
DK3059314T3 DK16154916.7T DK16154916T DK3059314T3 DK 3059314 T3 DK3059314 T3 DK 3059314T3 DK 16154916 T DK16154916 T DK 16154916T DK 3059314 T3 DK3059314 T3 DK 3059314T3
Authority
DK
Denmark
Prior art keywords
ser
fab fragment
artificial sequence
gly
thr
Prior art date
Application number
DK16154916.7T
Other languages
English (en)
Inventor
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Andrew George Popplewell
Andrew Paul Chapman
David John King
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3059314(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of DK3059314T3 publication Critical patent/DK3059314T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)

Claims (15)

1. Antistofmolekyle med specificitet for human TNFa, som er et Fab-fragment, der er kendetegnet ved, at det omfatter en let kæde med sekvensen givet i SEQ ID NO: 113 og en tung kæde med sekvensen givet i SEQ ID NO: 111.
2. Antistofmolekyle med specificitet over for humant TNFa, som er et Fab-fragment, der er kendetegnet ved, at det har en let kæde med sekvensen givet i SEQ ID NO: 113, og en tung kæde med sekvensen givet i SEQ ID NO: 111.
3. Antistof ifølge krav 1 eller 2, som er et modificeret Fab-fragment, hvor modifikationen er tilføjelse af en eller flere aminosyrer til C-terminalen af dets tunge kæde for at muliggøre binding af et effektor- eller reportermolekyle.
4. Modificeret Fab-fragment ifølge krav 3, hvor de yderligere aminosyrer danner en modificeret hængselregion, som indeholder en eller flere cysteinrester, hvortil effektor-eller reportermolekylet kan være bundet.
5. DNA, som koder for de tunge og lette kæder af antistofmolekylet, som er et Fab-fragment, ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4.
6. DNA ifølge krav 5 omfattende sekvensen vist i SEQ ID NO: 110 og 112.
7. Klonings- eller ekspressionsvektor indeholdende DNA'et ifølge krav 5 eller 6, hvor ekspressionsvektoren eventuelt er en E. coli ekspressionsvektor.
8. Værtscelle transformeret med vektoren ifølge krav 7 eller en første vektor kodende for den lette kæde af et Fab-fragment ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4, og en anden vektor kodende for den tunge kæde af Fab-fragmentet ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4.
9. Fremgangsmåde til fremstilling af antistofmolekylet, som er et Fab-fragment ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4, omfattende dyrkning af værtscellen ifølge krav 8 og isolering af antistofmolekylet, som er et Fab-fragment eller modificeret Fab-fragment.
10. Fremgangsmåde til fremstilling af antistofmolekylet, som er et Fab-fragment ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4, omfattende dyrkning af E. coli omfattende en E. coli ekspressionsvektor ifølge krav 7 og isolering af antistofmolekylet, som er et Fab-fragment eller modificeret Fab-fragment.
11. Fremgangsmåde til fremstilling af antistofmolekylet, som er et Fab-fragment eller modificeret Fab-fragment ifølge krav 10, hvor antistofmolekylet, som er et Fab-fragment eller modificeret Fab-fragment, er målrettet periplasmaet.
12. Terapeutisk sammensætning omfattende antistofmolekylet, som er et Fab-fragment ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4.
13. Antistofmolekyle, der er et Fab-fragment ifølge krav 1 eller 2 eller et modificeret Fab-fragment ifølge krav 3 eller 4, der har specificitet for human TNFa til anvendelse til behandling af en akut eller kronisk immun- eller immunregulatorisk sygdom, en infektion, en neurodegenerativ sygdom eller en ondartet sygdom.
14. Antistofmolekyle, der er et Fab-fragment eller modificeret Fab-fragment ifølge krav 13, til anvendelse til behandling af en inflammatorisk eller autoimmun lidelse.
15. Antistofmolekyle, der er et Fab-fragment eller modificeret Fab-fragment ifølge krav 14, til anvendelse til behandling af reumatoid artrit, osteoartrose, Crohns sygdom eller psoriasis.
DK16154916.7T 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet for human tumornekrosefaktor alpha, og anvendelse deraf DK3059314T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
EP10010795.2A EP2308975B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (1)

Publication Number Publication Date
DK3059314T3 true DK3059314T3 (da) 2019-02-18

Family

ID=9893121

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16154916.7T DK3059314T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet for human tumornekrosefaktor alpha, og anvendelse deraf
DK09176251.8T DK2230308T3 (da) 2000-06-06 2001-06-05 Antistofmolekyle, der har specificitet for human tumornekrosisfaktor-alfa, og anvendelse deraf
DK01934209.6T DK1287140T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet overfor human tumornekrosefaktor-alfa og anvendelse deraf
DK10010795.2T DK2308975T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet for human tumor nekrotiserende faktor alfa, og anvendelse deraf

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK09176251.8T DK2230308T3 (da) 2000-06-06 2001-06-05 Antistofmolekyle, der har specificitet for human tumornekrosisfaktor-alfa, og anvendelse deraf
DK01934209.6T DK1287140T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet overfor human tumornekrosefaktor-alfa og anvendelse deraf
DK10010795.2T DK2308975T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet for human tumor nekrotiserende faktor alfa, og anvendelse deraf

Country Status (43)

Country Link
US (4) US7012135B2 (da)
EP (4) EP1287140B1 (da)
JP (3) JP4064812B2 (da)
KR (1) KR20020047097A (da)
CN (1) CN1289671C (da)
AP (1) AP2092A (da)
AR (1) AR033978A1 (da)
AT (1) ATE451460T1 (da)
AU (1) AU783756B2 (da)
BE (1) BE2010C019I2 (da)
BG (1) BG66072B1 (da)
BR (2) BR0106682A (da)
CA (2) CA2380298C (da)
CY (6) CY1109889T1 (da)
CZ (1) CZ300737B6 (da)
DE (3) DE60140738D1 (da)
DK (4) DK3059314T3 (da)
EC (1) ECSP024210A (da)
ES (5) ES2337763T3 (da)
FR (1) FR10C0015I2 (da)
GB (2) GB0013810D0 (da)
HK (2) HK1051385A1 (da)
HU (4) HU230561B1 (da)
IL (3) IL147992A0 (da)
IS (2) IS2808B (da)
LT (1) LT2308975T (da)
LU (1) LU91674I2 (da)
MX (1) MXPA01013440A (da)
MY (1) MY136603A (da)
NL (1) NL300982I9 (da)
NO (4) NO334808B1 (da)
NZ (1) NZ516596A (da)
OA (1) OA12282A (da)
PE (1) PE20020292A1 (da)
PL (2) PL218516B1 (da)
PT (4) PT3059314T (da)
RU (1) RU2303604C2 (da)
SI (3) SI2308975T1 (da)
SK (1) SK288343B6 (da)
TR (1) TR201900227T4 (da)
TW (2) TWI316088B (da)
WO (1) WO2001094585A1 (da)
ZA (1) ZA200200097B (da)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DK1495056T3 (da) * 2002-03-20 2011-05-02 Ucb Pharma Sa Fremgangsmåde til analyse af antistofdisulfidisomere
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PL224150B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
JP4418745B2 (ja) * 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040126372A1 (en) * 2002-07-19 2004-07-01 Abbott Biotechnology Ltd. Treatment of TNFalpha related disorders
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CN101899106A (zh) 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004074345A2 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
ATE414106T1 (de) * 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
EP1656452B1 (en) * 2003-08-13 2007-02-14 Sandoz AG Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
JP2007501622A (ja) * 2003-08-13 2007-02-01 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドを精製するための方法
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
RU2425054C2 (ru) * 2005-06-01 2011-07-27 Микромет Аг Антитела против il2
WO2006131013A2 (en) 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2046385B1 (en) 2006-07-03 2015-03-25 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ATE476176T1 (de) * 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
WO2009097704A1 (en) * 2008-02-05 2009-08-13 Esbatech Ag Antigen-binding polypeptides against cartilage degeneration
KR101687032B1 (ko) * 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
CA2728004C (en) 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
RU2011135768A (ru) * 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
KR101758942B1 (ko) 2009-09-24 2017-07-17 유씨비 파마, 에스.에이. 박테리아 숙주 균주
EA201792376A3 (ru) 2009-10-23 2018-08-31 Милленниум Фармасьютикалз, Инк. Молекулы анти-gcc антитела и соответствующие композиции и способы
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
AU2011223547B2 (en) 2010-03-04 2016-05-05 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA3136084A1 (en) 2011-06-01 2012-12-06 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
CN103649124B (zh) 2011-07-13 2016-04-13 Ucb医药有限公司 表达重组dsbc的细菌宿主菌株
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
DK2758512T3 (da) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv Modifiecerede grampositive bakterier og anvendelser deraf
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EA039002B1 (ru) 2014-12-22 2021-11-19 Юсб Биофарма Спрл Способ получения белка
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
PL3464318T3 (pl) * 2016-06-02 2021-11-08 Abbvie Inc. Agonista receptora glukokortykoidowego i jego immunokoniugaty
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
AU2020215795A1 (en) 2019-01-31 2021-07-29 Numab Therapeutics AG Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating TGF-B signaling
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023046930A1 (en) 2021-09-24 2023-03-30 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
CA2218522A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
HUP1600016A2 (en) 2002-10-28
CA2707766C (en) 2013-05-21
BRPI0106682B1 (pt) 2020-10-13
AP2092A (en) 2010-02-28
JP2007105043A (ja) 2007-04-26
SI2230308T1 (sl) 2013-06-28
NO20020554D0 (no) 2002-02-04
BG66072B1 (bg) 2011-01-31
IL147992A0 (en) 2002-09-12
AR033978A1 (es) 2004-01-21
CZ2002837A3 (cs) 2002-05-15
AU6051101A (en) 2001-12-17
NZ516596A (en) 2004-07-30
GB0013810D0 (en) 2000-07-26
NL300982I9 (nl) 2019-05-06
SI2308975T1 (sl) 2016-11-30
BRPI0106682B8 (pt) 2021-05-25
NO20160694A1 (no) 2002-04-08
CY2010011I2 (el) 2012-01-25
NO2014026I1 (no) 2014-10-23
CN1289671C (zh) 2006-12-13
BR0106682A (pt) 2002-05-14
HUP1600483A2 (da) 2002-10-28
HUP0202346A3 (en) 2004-11-29
TWI316088B (en) 2009-10-21
ES2600080T3 (es) 2017-02-07
IL195085A0 (en) 2009-08-03
CY1114143T1 (el) 2016-07-27
PT1287140E (pt) 2010-03-08
PL353960A1 (en) 2003-12-15
CA2380298C (en) 2010-09-28
ES2403217T3 (es) 2013-05-16
DK2308975T3 (da) 2016-10-31
US20030026805A1 (en) 2003-02-06
PL212738B1 (pl) 2012-11-30
CA2380298A1 (en) 2001-12-13
RU2303604C2 (ru) 2007-07-27
EP3059314A1 (en) 2016-08-24
US20060233800A1 (en) 2006-10-19
FR10C0015I2 (fr) 2011-12-30
LU91674I2 (fr) 2010-05-31
CA2707766A1 (en) 2001-12-13
GB0128386D0 (en) 2002-01-16
DK1287140T3 (da) 2010-04-19
ATE451460T1 (de) 2009-12-15
CY1109889T1 (el) 2012-01-25
IS3016B (is) 2019-10-15
NO20020554L (no) 2002-04-08
NO341218B1 (no) 2017-09-11
DE122010000027I1 (de) 2010-08-12
AP2002002690A0 (en) 2002-12-31
PL399351A1 (pl) 2012-12-17
EP1287140B1 (en) 2009-12-09
FR10C0015I1 (da) 2010-04-16
BE2010C019I2 (da) 2020-08-20
BG106278A (bg) 2002-12-29
TWI353358B (en) 2011-12-01
GB2366800A (en) 2002-03-20
NO20131316L (no) 2002-04-08
ES2707714T3 (es) 2019-04-04
JP5185143B2 (ja) 2013-04-17
NO2014026I2 (no) 2018-02-14
GB2366800B (en) 2005-01-19
DE60140738D1 (de) 2010-01-21
JP4064812B2 (ja) 2008-03-19
HU230561B1 (hu) 2016-12-28
WO2001094585A1 (en) 2001-12-13
DK2230308T3 (da) 2013-05-06
CY1121173T1 (el) 2020-05-29
SK3152002A3 (en) 2002-07-02
JP4476989B2 (ja) 2010-06-09
EP2308975A1 (en) 2011-04-13
HU230553B1 (hu) 2016-11-28
ES2337763T3 (es) 2010-04-29
HK1051385A1 (en) 2003-08-01
US20020151682A1 (en) 2002-10-17
ES2230975A1 (es) 2005-05-01
PE20020292A1 (es) 2002-05-08
EP3059314B1 (en) 2018-10-24
EP2230308A1 (en) 2010-09-22
IL147992A (en) 2009-06-15
CY2019018I2 (el) 2020-05-29
CY1118220T1 (el) 2017-06-28
CZ300737B6 (cs) 2009-07-29
ES2230975B2 (es) 2007-04-16
NL300982I1 (da) 2019-05-01
LT2308975T (lt) 2016-11-10
PL218516B1 (pl) 2014-12-31
HK1148776A1 (en) 2011-09-16
US7977464B2 (en) 2011-07-12
OA12282A (en) 2006-05-11
PT2308975T (pt) 2016-11-14
US7186820B2 (en) 2007-03-06
IS6217A (is) 2002-01-03
JP2003535591A (ja) 2003-12-02
NO339282B1 (no) 2016-11-21
US20080269465A1 (en) 2008-10-30
TR201900227T4 (tr) 2019-02-21
PT3059314T (pt) 2019-02-01
EP1287140A1 (en) 2003-03-05
DE10192353T1 (de) 2003-05-22
MY136603A (en) 2008-10-31
CY2019018I1 (el) 2020-05-29
HUS1700013I1 (hu) 2017-08-28
AU783756B2 (en) 2005-12-01
EP2230308B1 (en) 2013-01-23
TW200817430A (en) 2008-04-16
JP2009171966A (ja) 2009-08-06
EP2308975B1 (en) 2016-08-10
HU230669B1 (hu) 2017-07-28
IS2808B (is) 2012-09-15
HUP0202346A2 (en) 2002-10-28
SI1287140T1 (sl) 2010-04-30
US7012135B2 (en) 2006-03-14
CN1383450A (zh) 2002-12-04
ECSP024210A (es) 2002-05-23
NO334808B1 (no) 2014-06-02
US7402662B2 (en) 2008-07-22
ZA200200097B (en) 2003-01-06
CY2010011I1 (el) 2012-01-25
KR20020047097A (ko) 2002-06-21
MXPA01013440A (es) 2003-09-04
PT2230308E (pt) 2013-05-03
LU91674I9 (da) 2019-01-03
SK288343B6 (sk) 2016-04-01

Similar Documents

Publication Publication Date Title
DK3059314T3 (da) Antistofmolekyler, der har specificitet for human tumornekrosefaktor alpha, og anvendelse deraf
SK288706B6 (sk) Molekuly protilátky, ktoré sú špecifické pre humánny nádorový nekrotický faktor alfa a ich použitie